Navigation Links
Byetta Lawsuit News: Bernstein Liebhard LLP Notes Establishment of Multidistrict Litigation For Federal Lawsuits Involving Byetta, Similar Diabetes Drugs
Date:8/27/2013

New York, New York (PRWEB) August 27, 2013

Byetta lawsuits (http://www.byettalawsuit2013.com/), as well as all other federally-filed product liability claims involving the incretin mimetic class of diabetes drugs, have been transferred to the U.S. District Court, Southern District of California, for pretrial proceedings, Bernstein Liebhard LLP reports. According to a Transfer Order issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on August 26, 2013, the consolidated proceeding will be presided over by the Honorable Anthony J. Battaglia. All of the claims pending in the newly-established multidistrict litigation involve allegations of a possible association between incretin mimetics, including Byetta, and pancreatic cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)

“Our Firm has received numerous inquiries from patients who used Byetta and other diabetes drugs in this class, and who are concerned that these medications resulted in their pancreatic cancer diagnosis. We agree that a consolidated proceeding will provide an efficient means of resolving claims involving incretin mimetics, including Byetta lawsuits,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free legal evaluations to alleged victims of Byetta pancreatic cancer, as well as pancreatitis and thyroid cancer.

Byetta and Pancreatic Cancer
Byetta and other incretin mimetics work to regulate insulin production in the pancreas by mimicking the action of incretin, a hormone produced in the intestinal tract. However, since its launch in 2005, the U.S. Food & Drug Administration (FDA) has released a number of Byetta warnings regarding the medication’s potentially harmful effects on the pancreas. In 2008, for
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Federal Judicial Panel Considering Byetta Lawsuit Consolidation, Rottenstein Law Group LLP Reports
2. Byetta Pancreatic Cancer Allegation Lawsuits Update: Resource4thePeople Awaiting Federal Court Decision on Possible Creation of Multidistrict Litigation
3. Byetta Lawsuit Investigation Being Conducted by Bernstein Liebhard LLP On Behalf of Byetta Users Diagnosed with Pancreatic Cancer, Pancreatitis, and Thyroid Cancer
4. Byetta Lawsuit - Claims Move Forward, as Panel Considers Consolidation of Federal Claims Involving Byetta and Similar Diabetes Drugs, Bernstein Liebhard LLP Reports
5. Byetta Lawsuit News: Bernstein Liebhard LLP Awaits Decision on Establishment of Federal Multidistrict Litigation for Byetta Pancreatic Cancer Claims
6. Federal Byetta, Victoza, Januvia Lawsuits Could See Consolidation This Month, Rottenstein Law Group LLP Reports
7. Rottenstein Law Group LLP Acknowledges BMJ Study of Risks of Byetta, Januvia
8. Byetta Pancreatic Cancer Lawsuit News: Bernstein Liebhard LLP Comments on BMJ Investigation Finding Incretin Mimetic Risks Were Downplayed
9. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
10. Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
11. Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... King of Prussia, PA (PRWEB) October 22, 2014 ... Group, is recognized as an industry leader with over ... industry award winning team leader in the areas related ... In addition, Mr. Carlson is an Editorial Advisory Board ... Group Healthcare Council Educator. Blue Fin Group is ...
(Date:10/22/2014)... Two sisters in high school have developed ways to ... Krishen use electronic stethoscopes, which electronically amplify body sounds, ... or heartbeats. Ilina, a senior at Port Huron ... way to detect early lung damage in people exposed ... recorded one breath cycle each from 16 smokers, 25 ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is ... repair a damaged mitral valve as the heart continues ... by Abbott Vascular , is designed to treat ... in which the heart’s mitral valve leaflets fail to ... heart’s left ventricle into the left atrium. The heart ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... 21 Patient Safety Week was March 8-14. ... (1979), the pulse oximeter (1983) and the brain activity ... of these technological devices clearly improved patient safety. This ... a forward thinking, caring physician."Until now, I,ve never publicly ...
... MI based company, is researching and developing decontamination testing equipment ... use their extensive knowledge of cleaning and decontamination to develop repeatable ... ... (Vocus) April 21, 2009 -- Midbrook, Inc ., a Jackson, ...
... medical billing company, announces services that help medical professionals go paperless, ... the healthcare industry. , ... (PRWEB) April 21, 2009 ... upon the nation,s healthcare system to step up efforts to convert ...
... worldwide for self-directed home treatment of the most common cause of ... ... Edmonton, Canada (PRWEB) April 14, 2009 -- A new ... treatment of BPPV (Benign Paroxysmal Positional Vertigo), the most common ...
... 21 The University HealthSystem Consortium (UHC) today ... for employee satisfaction surveys and consulting services to ... agreement, which has 2 optional 1-year renewal periods, ... an extensive array of customized surveys and analyses ...
... the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory ... of supplemental new drug applications (sNDA) for SEROQUEL XR (quetiapine ... disorder (MDD) and generalized anxiety disorder (GAD).The Advisory Committee concluded: ... SEROQUEL XR was shown to be ...
Cached Medicine News:Health News:American Society of Anesthesiologists Recent Public Debate Comes to Dead End 2Health News:American Society of Anesthesiologists Recent Public Debate Comes to Dead End 3Health News:Midbrook Tackles Medical Decontamination 2Health News:Midbrook Tackles Medical Decontamination 3Health News:Dr. America Comes to Obama's Aid, Helps Doctors Digitize 2Health News:Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo 2Health News:Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo 3Health News:University HealthSystem Consortium Selects Morehead to Provide Employee Satisfaction and Consulting Services 2Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 2Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 3Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 4Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 5Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 6Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 7
(Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... 27, 2011 As a result of the flagging ... dangerous to their health, according to Consumer Reports, annual ... take a prescription medicine told pollsters they,d cut health-care ... or medical procedure, declining tests, or ordering cheaper drugs ...
... ( http://www.myprgenie.com ) --  Texans for Stem Cell Research ... panel of stem cell experts from Texas and around ... TSCR Second Annual Educational Symposium with a welcome address ... Health Affairs for The University of Texas System. The ...
Cached Medicine Technology:Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 2Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 3Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 4Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 5World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 2World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 3World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 4World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 5
Malaria device / strip (3 line, P.f/P.v Ag Test-pLDH)...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
BioSign® Malaria - Rapid Malaria Antigen Test...
Medicine Products: